Pathogenesis of peptic ulcer.

K. Ivey

DOI: https://doi.org/10.1111/J.1445-5994.1974.TB03150.X

1974-02-01

Australian and New Zealand Journal of Medicine

Abstract:

What problem does this paper attempt to address?

A Rare Case of Acquired Factor VIII Deficiency in an Elderly Male With a History of Rheumatoid Arthritis

Shubhangi Shah,Michael Tseng,Ashimiyu Durojaiye

DOI: https://doi.org/10.7759/cureus.44169

2023-08-26

Cureus

Abstract:Acquired hemophilia A (AHA) or factor VIII (FVIII) deficiency is caused by autoantibodies targeting FVIII in the blood coagulation pathway; it is a rare condition making it challenging to diagnose. A timely diagnosis is crucial, without which there is a risk of catastrophic bleeding. We report a case of a patient with a history of duodenal arteriovenous malformations, previously on apixaban, who presented with four days of melena. On admission he was found to have a hemoglobin of 5.7 and elevated partial thromboplastin time (PTT), promoting further workup showing FVIII levels of <1%, with a mixing study that failed to correct suggesting the presence of inhibitors against FVIII. Other characteristics of this patient's cases included controlled rheumatoid arthritis without detectable rheumatoid factor or increased erythrocyte sedimentation rate (ESR). The patient was initially treated with prednisone and intravenous immunoglobulins, but an insufficient response prompted the initiation of recombinant factor VII, rituximab, and cyclophosphamide during hospitalization.
Zik1, a Transcriptional Repressor That Interacts with the Heterogeneous Nuclear Ribonucleoprotein Particle K Protein*

O. Denisenko,B. O'Neill,J. Ostrowski,I. van Seuningen,K. Bomsztyk

DOI: https://doi.org/10.1074/jbc.271.44.27701

IF: 5.485

1996-11-01

Journal of Biological Chemistry

Abstract:The heterogeneous nuclear ribonucleoprotein particle (hnRNP) K protein is comprised of multiple modular domains that serve to engage a diverse group of molecular partners including DNA, RNA, the product of the proto-oncogene vav, and tyrosine and serine/threonine kinases. To identify additional K protein molecular partners and to further understand its function, we used a fragment of K protein as a bait in the yeast two-hybrid screen. The deduced primary structure of one of the positive clones revealed a novel zinc finger protein, hereby denoted as Zik1. In addition to the nine contiguous zinc fingers in the C terminus, Zik1 contains a KRAB-A domain thought to be involved in transcriptional repression. Zik1 and K protein bound in vitro and co-immunoprecipitated from cell extracts indicating that in vivo their interaction is direct. Expression of Gal4 DNA-binding domain-Zik1 fusion protein repressed a gene promoter bearing Gal4-binding elements, indicating that from cognate DNA elements Zik1 is a transcriptional repressor. The known diverse nature of K protein molecular interactions and now the identification of a K protein partner that is a transcriptional repressor lends support to the notion that K protein is a remarkably versatile molecule that may be acting as a docking platform to facilitate communication among molecules involved in signal transduction and gene expression.
Elimination of antibacterial activities of non-peptide luteinizing hormone-releasing hormone (LHRH) antagonists derived from erythromycin A.

J. Randolph,D. Sauer,F. Haviv,A. Nilius,J. Greer

DOI: https://doi.org/10.1016/J.BMCL.2003.12.059

IF: 2.94

2004-03-22

Bioorganic & Medicinal Chemistry Letters

Abstract:
Recognition of the unique bleeding pattern and laboratory findings in acquired haemophilia A facilitates prompt treatment of a life-threatening disorder

Hunter Cameron,Juliana Perez Botero

DOI: https://doi.org/10.1136/bcr-2021-244238

2021-08-03

Abstract:Acquired haemophilia A (AHA) is an uncommon but severe acquired bleeding disorder caused by the development of antibodies against clotting factor VIII, impairing secondary haemostasis. It is more common in older individuals and characteristically presents with spontaneous soft tissue bleeding that can rapidly become life-threatening. Definitive treatment requires immunosuppression to eradicate anti-FVIII antibodies, while providing haemostatic support to manage bleeding. Transfusions of fresh frozen plasma or cryoprecipitate, typically used to treat severe bleeding, are ineffective in patients with AHA. Instead, highly specialised clotting factor concentrates are required. While the appearance and extent of the soft tissue bleeding and the markedly prolonged activated partial thromboplastin time are characteristic, lack of familiarity with this disease process can lead to significant treatment delays. We report the clinical course and management of a 65-year-old woman who presented with severe anaemia of unclear aetiology with unrecognised soft tissue bleeding who was subsequently diagnosed with AHA.
Acquired hemophilia A in a woman with systemic lupus erythematosus: A case report and review of literature

Pan Shen,Jing Li,Shenghao Tu,Gang Chen,Chao Chen

DOI: https://doi.org/10.1097/MD.0000000000022926

2020-10-23

Abstract:Rationale: Acquired hemophilia A (AHA) is a rare autoimmune disease caused by autoantibodies directed against the activity of factor VIII (FVIII) and presents with prolonged bleeding. 5.7% of systemic lupus erythematosus (SLE) patients are affected by AHA. Patient concerns: A 51-year-old female patient with SLE presenting with the fatigue and spontaneous clinical bleeding symptoms such as hematuria and ecchymoses for 1 week. Diagnosis: Laboratory examinations revealed prolongation of the activated partial thromboplastin time (APTT) (65.7 s), decreased FVIII activity (1.4%), and a titer of FVIII inhibitors of 8.5 Bethesda units/mL. Interventions: Transfusion of recombinant human FVIII (ADVATE) in combination with intravenous methylprednisolone, cyclophosphamide, plasmapheresis, and fresh frozen plasma successfully stopped the bleeding and reduced the level of FVIII inhibitor. Outcomes: The size of the hematoma slowly decreased. The skin ecchymosis was gradually absorbed, the hemoglobin count increased, and the coagulation index gradually improved. There was no new bleeding or bleeding site. The patient was discharged and transferred to a local hospital for hospice care. Lessons: AHA in a patient with SLE is rare. Once it occurs, it can be life-threatening. Clinicians should remain aware that because some cases of AHA may have features of SLE, appropriate distinction and diagnosis of these different but associated diseases is necessary.
Acquired Hemophilia: A Rare Complication of Pediatric Idiopathic Multicentric Castleman Disease

Lauren E. Appell,Joana M. Mack,Jason E. Farrar,Sydney N. Roper,Matthew R. Savage,Soumya Pandey,Shelley E. Crary

DOI: https://doi.org/10.1542/peds.2023-063168

2024-03-21

PEDIATRICS

Abstract:Acquired hemophilia is caused by acquired autoantibodies to 1 of the factors of the coagulation cascade, usually factor VIII or IX, and is an exceedingly rare phenomenon in children. The finding of an acquired factor VIII inhibitor in a pediatric patient with idiopathic multicentric Castleman disease has never been reported. Patients with acquired hemophilia can have life-threatening bleeds that are refractory to blood product support, requiring bypassing agents to manage bleeding symptoms. We present the novel finding of acquired hemophilia resulting from an autoantibody to factor VIII in a pediatric patient with idiopathic multicentric Castleman disease and discuss the optimal management of bleeding in a patient with acquired hemophilia.

pediatrics
Chemicals introduced in the processing of foods.

F. Bing

DOI: https://doi.org/10.2105/AJPH.40.2.156

1950-02-01

American Journal of Public Health and the Nations Health

Abstract:
Acquired hemophilia A with venous thrombosis:report of a case and review of the literature

TAO Hong,OUYANG Jian,ZHOU Rong-fu,SHAO Xiao-yan,LI Ping,XU Yong,CHEN Bing,ZHANG Qi-guo,YANG Yong-gong

DOI: https://doi.org/10.3877/cma.j.issn.1674-0785.2012.15.042

2012-01-01

Abstract:Objective To understand better the clinical features of acquired hemophilia A with venous thrombosis.Methods The etiology,pathogenesis,symptom,diagnosis,and treatment of acquired hemophilia A with venous thrombosis were discussed after retrospectively analysis of the prestentions of the case report and the literature.Results Acquired hemophilia A is a rare bleeding disease caused by autoantibodies directed against clotting factor Ⅷ.This autoimmune disorder most commonly occurs in the elderly.In approximately 50% of cases,it is idiopathic,while the remaining cases may be associated with autoimmune diseases,underlying hematologic or solid cancers.Hemorrhages in patients with acquired hemophilia A involve most frequently soft tissues.The associate prothrombotic risk factors(both congenital,but mainly acquired)are probably responsible for the occurrence of thrombosis in some of acquired hemophilia A patients.The two treatment priorities are to arrest the acute bleeding with substitution therapy and to eradicate the factor Ⅷ autoantibody with immunosuppressive therapy.Anti-coagulation and anti-thrombosis therapy may enhance the bleeding tendency in acquired hemophilia A patients.The report case was an 66-year-old man with gastric cancer.He had a prolonged APTT pre-operation and soft tissue hematoma post-operation.F Ⅷ inhibitor title was 128 Bethesda Unit.He was treated with prednisone,cyclophosphamide,and high-dose intravenous immunoglobulin to eradicate the inhibitor,factor concentrates(human F Ⅷ concentrates and prothrombin complex concentrate)transfusion to arrest the acute bleeding.Transfusion of prothrombin complex concentrate was discontinued after his right femoral and calf muscular venous thrombosis developed.He was treated with combined chemotherapy containing Paclitaxel for three cycles.The signs of hematoma and thrombosis disappeared and coagulation tests returned to normal with inhibitor undetected.Conclusions Acquired hemophilia A with venous thrombosis is a very rare occurrence of hemorrhagic diathesis and veno-occlusive disorder with treatments incompatible.Correct diagnosis and comprehensive and individual therapies are the key to successive treatment.
Postpartum Acquired Hemophilia A

Khawaja O Omar,William Sebastian,Suzanne Kemper

DOI: https://doi.org/10.55729/2000-9666.1382

2024-09-09

Abstract:Acquired hemophilia A (AHA) is a bleeding disorder that occurs from aberrant production of autoantibodies that target factor VIII. The underlying cause of AHA is unclear but can present postpartum. Very few cases have reported instances of AHA coexisting with other hematological disorders, such as sickle cell trait (SCT). Although rare and no direct correlation between the two, critical situations involving intractable bleeding can intensify the severity of these disorders. A 31-year-old pregnant female with a medical history significant for SCT presented to the hospital for a C-section. Shortly after the procedure she experienced intractable bleeding from multiple sites. Initial lab work yielded an isolated increase in activated partial thromboplastin time (aPTT). Further investigation showed abnormal mixing studies, reduced factor VIII activity and the presence of factor VIII antibodies. The patient was diagnosed with postpartum AHA (PAH) and treated with activated Factor VII and prednisone. PAH is an uncommon bleeding disorder that commonly occurs one to four months postpartum and presents as excessive bleeding elevated aPTT, abnormal mixing studies, and reduced factor VIII levels with abnormally high inhibitor levels. Despite an unknown identifiable etiology, treatment hinges upon establishing hemostasis and eradicating the aberrant generated factor VIII inhibitors. The association of AHA and other hematological disorders is not yet elucidated.
[Systemic Lupus Erythematosus with Acquired Hemophilia A: a Case Report].

F Yang,Y S Zhou,Y Jia

DOI: https://doi.org/10.19723/j.issn.1671-167x.2018.06.030

2018-01-01

Abstract:Acquired hemophilia A (AHA) is anunusual disease resulting from autoantibodies (inhibitors) against coagulation factor VIII (FVIII) and clinically manifests as bleeding, which sometimes can cause potentially limb-threatening or life-threatening situations. AHA is associated with cancers, auto-immune disorders, infections, dermatologic conditions and certain medications, among which it is commonly secondary to multiple rheumatologic conditions, such as rheumatoid arthritis, systemic lupus erythematosus (SLE), pollymyositis, autoimmune hemolytic anemia and undifferentiated connective tissue disease. In autoimmune diseases, it may be the result of autoantibody producing against FVIII, and some cases of AHA may act as the first manifestation of SLE. AHA should be suspected in patients who have spontaneously hemorrhagic events with an isolated prolonged activated partial thromboplastin time (APTT), reduced FVIII activity and a negative lupus anticoagulant (LA). When FVIII inhibitor is found, it can be diagnosed. The management of AHA focuses on the following goals: (1) controlling and preventing bleeding, (2) eradication of the inhibitor, (3) treatment of the underlying disease. Here, a case of AHA in a patient with lupus is reported. A 53-year-old man with a 4-year history of SLE developed arthralgia and ecchymotic skin lesions after arthrocentesis of knee joint. Ultrasound confirmed the presence of an intramuscular hematoma. Coagulation tests revealed that FVIII activity reduced to 1% and a prolonged APTT (92.2 s), FVIII inhibitors were found to be as high as 60.0 Bethesda Units. Initial treatments with methylprednisolone 200 mg/d were started but new hemorrhagic manifestation occurred and hisbiological indexes were not good. Then the patient was treated with intravenous pulse corticosteroids (methylprednisolone 500 mg/d), intravenous cyclophosphamide, and also plasma and prothrombin complex infusion. Subsequently, FVIII activity returned within normal ranges, FVIII inhibitors decreased and clinical improvement was significantly obtained. The patient's condition kept stable till now.Hemorrhagic events due to production of antibodies directed against coagulation factors were rarely observed in SLE and attentions should be paid to the association between SLE and AHA.Bypass treatment was considered as the immediate antihemorrhagic treatment. Corticosteroid combined with immunosuppressor was recommended as the main therapy to eradicate the inhibitors. However we still lack the therapeutic guidelines and standardized treatment in patients of AHA with SLE at present.
Retroperitoneoscopic renal pedicle lymphatic disconnection for chyluria.

Jun Jiang,F. Zhu,F. Jin,Qin Jiang,Luofu Wang

IF: 6.133

2003-11-01

Chinese Medical Journal

Abstract:OBJECTIVE To report our experiences in retroperitoneoscopic renal pedicle lymphatic stripping for chyluria. METHODS Six cases of filarial chyluria were admitted to our hospital from November 2001 to June 2002. Of these cases, 4 were men and 2 women, with age ranging from 34 to 52 years (mean, 42 years). Diagnosis was made by using urine test for the presence of chyle and fat globule, cystoscopy, excretory urogram and retrograde pyelography. Chyluria was found on the left renal unit in 2 cases and on the right side in 4 cases. The technique of retroperitoneoscopic management of chyluria consisted of nephrolympholysis, hilar vessel stripping and ureterolympholysis. RESULTS Operative time ranged from 69 to 120 minutes (mean, 95 minutes). Intraoperative blood loss was 50-180 ml (mean, 85 ml). Chyluria disappeared in all patients immediately after operation. Mild hematuria occurred in 4 cases within 12 hours and disappeared at 24 hours. Subcutaneous emphysema around the lesions was found in 2 cases and was spontaneously absorbed 3 days after the treatment. There was no lymphatic leak at the lesions. The patients were discharged from the hospital 5-9 days after the treatment. All patients gained weight and their haemoglobin and serum protein increased by 13.5 g/L and 3.66 g/L respectively. No chyluria recurrence was reported during 1-1.6 years follow-up. CONCLUSIONS Retroperitoneoscopic renal pedicle lymphatic disconnection for chyluria is a safe, effective and efficient surgical procedure with minimal invasion, less pain, lower morbidity, short hospital stay and rapid recovery.
Acquired hemophilia A as a disease of the elderly: A comprehensive review of epidemiology, pathogenesis, and novel therapy

Andrea Lehoczki,Mónika Fekete,Gábor Mikala,Imre Bodó

DOI: https://doi.org/10.1007/s11357-024-01317-7

2024-09-23

GeroScience

Abstract:Abstract Acquired hemophilia A (AHA) is a rare autoimmune bleeding disorder characterized by the development of neutralizing autoantibodies (inhibitors) against coagulation factor VIII (FVIII). This review provides an in-depth exploration of AHA, covering its epidemiology, pathogenesis, clinical presentation, diagnosis, complications, and treatment strategies, focusing on recent advancements. AHA can manifest in both men and women with no prior bleeding history. The annual incidence is estimated to be approximately 1 case per million individuals in the general population. The incidence increases significantly with age: the incidence among individuals aged 60 years or older is approximately 3 to 4 cases per million individuals per year. Typically, patients present with an acquired bleeding disorder that is characterized by an isolated, prolonged activated partial thromboplastin time stemming from FVIII deficiency. Diagnosis relies on the detection of neutralizing antibodies using the Nijmegen-modified Bethesda assay. Hemostatic control strategies involve bypassing agents like recombinant activated factor VII, activated prothrombin complex concentrate, and recombinant porcine FVIII for bleeding patients. Emicizumab, a novel bypassing agent, exhibits several potential advantages. In the realm of immunosuppressive treatment for inhibitor eradication, the CyDRi regimen emerged as a remarkable advancement, significantly enhancing the outlook for the management of AHA even in the elderly frail population.

geriatrics & gerontology,gerontology
Acquired bleeding disorders

Andreas Tiede,Sophie Susen,Ton Lisman

DOI: https://doi.org/10.1111/hae.14995

2024-04-01

Haemophilia

Abstract:Abstract Acquired bleeding disorders can develop in previously healthy people irrespective of age or gender but are particularly common in patients with certain underlying conditions. Here, we review recent advances in the management of acquired haemophilia A (AHA), acquired von Willebrand syndrome (AVWS), and patients with hemostatic abnormalities due to chronic liver disease (CLD). Patients with AHA can now benefit from prophylaxis with emicizumab, a therapeutic antibody that mimics the function of activated coagulation factor VIII. The treatment of AVWS remains challenging in many situations and requires careful consideration of the underlying condition. Haemostatic abnormalities in CLD are often compensated by proportional reduction in pro and anti‐haemostatic factors resulting in sustained or even increased thrombin generation. Consequently, bleeding in CLD is rarely caused by haemostatic failure and infusion of plasma or coagulation factor concentrates may not be effective.

hematology
S3627 Acquired Hemophilia A as a Cause of Obscure Gastrointestinal Bleeding

Lauren Davis,Erin Hollis,Julianna Tantum,Stephanie Rivera Morales,Nicole Albert

DOI: https://doi.org/10.14309/01.ajg.0001043876.57234.4d

2024-10-26

The American Journal of Gastroenterology

Abstract:Acquired Hemophilia A (AHA) is a rare, acquired bleeding disorder characterized by the production of autoantibodies to clotting Factor VIII. Patients with AHA most often develop spontaneous cutaneous and intramuscular bleeding, though massive gastrointestinal (GI) bleeding has been reported. We present a case of a patient with acute blood loss anemia with recurrent GI bleeding despite multiple unrevealing endoscopic evaluations, ultimately found to have Acquired Hemophilia A.

gastroenterology & hepatology
Acquired Hemophilia A Diagnosed Based on Gross Hematuria: A Case Report and Literature Review

Kenichi Hata,Junichiro Kato,Yusuke Takahashi,Shun Saito,Keigo Sakanaka,Takahiro Kimura

DOI: https://doi.org/10.1155/2024/2760153

2024-08-12

Abstract:Acquired hemophilia A (AHA) is an acquired bleeding disorder caused by neutralizing antibodies (inhibitors) against Coagulation Factor VIII (FVIII:C), causing sudden hemorrhagic symptoms (i.e., subcutaneous bleeding, intramuscular bleeding, and hematuria). Herein, this study is aimed at presenting a case of AHA diagnosed based on hematuria and reviewing patients who were diagnosed with AHA due to hematuria. A 67-year-old woman was referred to Atsugi City Hospital with painless gross hematuria that began 4 weeks before presentation. Contrast-enhanced computed tomography (eCT) revealed an approximately 2 cm mass in the right renal pelvis, and the patient's activated partial thromboplastin time (APTT) was elevated (61.4 s). The day after the endoscopic biopsy, the patient was in shock due to a large retroperitoneal hematoma. Although her condition stabilized after intravenous radioembolization, she underwent emergency surgeries several times because of rebleeding within the next 3 weeks. At that time, APTT was more prolonged at 106.4 s, and the FVIII:C level was 2%. Mixing tests showed an upwardly convex curve after 2-h incubation, indicating the presence of an inhibitor. Factor VIII inhibitor titer was ≥5.1 Bethesda unit (BU)/mL. A combined product of Plasma-Derived Factors VIIa and X (pd-FVIIa/FX), as second-line hemostatic therapy, as well as cyclophosphamide (CYP), were administered after Recombinant Activated Factor VIIa (rFVIIa) had been ineffective. Following this, the Factor VIII inhibitor titer was undetectable, FVIII:C levels were restored, and APTT decreased to within the normal range. Gross hematuria was significantly alleviated. However, the patient died of cytomegalovirus and fungal infections due to prolonged immunosuppressive therapy. Although AHA diagnosed based on hematuria may have a better prognosis than others, there have been occasional cases with severe outcomes. APTT, detected upon initial hematological testing in patients with hematuria, may be a potential indicator of an existing AHA.
Acute Abdominal Crisis in Type A Hemophilia: Unraveling Retroperitoneal Hematoma: A Case Report

Hisham A Althobaiti,Bahjat F Alabou Houseen,Eyad M Alsaqqa,Abdulhameed Fouad Sarriyah,Khalid E Althobaiti,Abdullah O Al Sharif,Jehan F Sarriyah

DOI: https://doi.org/10.12659/AJCR.944694

2024-08-20

Abstract:BACKGROUND Classical hemophilia A, an X-linked recessive disorder, is characterized by an inability to produce factor VIII in normal quantities. This condition, also leading to factor IX deficiency, underpins the bleeding disorder known as hemophilia A. Among the complications of this illness, spontaneous retroperitoneal hematoma is rare but can be associated with congenital coagulopathies such as von Willebrand disease or hemophilia A. This type of spontaneous internal bleeding has been the subject of a limited number of studies. CASE REPORT A 38-year-old man with a known diagnosis of hemophilia A presented to the Emergency Department exhibiting acute pain in the right lower abdomen. A computed tomography scan of the abdomen identified a right-sided retroperitoneal mass, suspected to be a hematoma. Within 7 h after admission, the patient experienced significant drops in the hemoglobin level and platelet count. He was administered packed red blood cells, fresh frozen plasma, and platelet transfusions prior to transfer to the Intensive Care Unit. There, he was treated with factor VIII and recombinant factor VIIa, coupled with stringent monitoring. Following clinical and laboratory findings and stabilization, he was discharged with specific medications, and a follow-up appointment was scheduled. CONCLUSIONS Spontaneous retroperitoneal hematoma in patients with hemophilia A is a rare and grave emergency. This case underscores the need for precise diagnostic approaches, tailored management strategies, and vigilant surveillance to prevent and mitigate the potentially life-threatening complications associated with spontaneous hemorrhage in this population.
Acquired hemophilia associated with bullous pemphigoid: a case report

Xiangning Qiu,Guiying Zhang,Rong Xiao,Jing Zhang,Ying Zhou,Ganqun Li,Kailin Yan,Qianjin Lu

Abstract:The development of factor VIII inhibitors in non-hemophilic patients is rare and may occur in healthy individuals, mostly elderly and women in postpartum period, and in patients with malignant neoplasia or autoimmune diseases, such as bullous pemphigoid. We described the case of a 60-year-old female patient who developed bullous pemphigoid for 3 month and presented with bleeding tendency and hematoma in the tongue. Therapy with methylprednisolone, cyclophosphamide, intravenous immunoglobulin and factor VIII reposition was instituted, resulting in a remission of the bleeding and negativity for antibodies against factor VIII titers. We concluded that, despite its rarity, the presence of acquired factor VIII inhibitors should be investigated when patients with autoimmune diseases develop bleeding manifestations.
Acquired Factor VIII Deficiency Presenting as Gross Hematuria in a Hispanic, Pregnant Patient with Previously Undiagnosed Connective Tissue Disease

Christine Loftis,Emilia C Dulgheru,Rosa White

DOI: https://doi.org/10.1155/2021/3666270

2021-11-17

Abstract:Acquired factor VIII deficiency is a bleeding disorder caused by the presence of autoantibodies against clotting factor VIII. We report a case of a 24-year-old pregnant woman who presented with gross hematuria secondary to acquired factor VIII deficiency in the presence of a previously undiagnosed connective tissue disease. This article includes a literature review of pregnancy-related cases of acquired factor VIII deficiency. We also reviewed various therapeutic approaches for the management of the acquired factor inhibitor which include achieving hemostasis and elimination of the inhibitor via immunosuppressive agents. This case report describes the rare presentation of acquired factor VIII deficiency related to pregnancy and highlights the importance of considering a factor VIII inhibitor in the differential diagnosis of patients who present with bleeding and prolonged PTT during the peripartum and postpartum periods.
[Acquired hemophilia A associated with bullous pemphigoid and multiple myeloma: a case report]

Élise Sourdeau,Sylvain Clauser,Romain Prud'Homme,Valérie Bardet,Leyla Calmette

DOI: https://doi.org/10.1684/abc.2018.1405

2019-04-01

Abstract:Acquired hemophilia A (AHA) is a rare and potentially severe bleeding disorder caused by circulating autoantibodies directed against factor (F) VIII. Apart from idiopathic cases, AHA is associated with autoimmune diseases, cancers, use of medications, pregnancy and the post-partum period. We report the case of a 78-year-old a male patient presenting with symptoms of a hematoma after a fall three days previously. He is medically followed for multiple myeloma and bullous pemphigoid. Laboratory investigations revealed isolated and recent increased of activated partial thromboplastin time (80,6/32,1s) and a markedly low FVIII activity (< 1%). The high-titer of FVIII inhibitor (19 Bethesda units/mL) confirmed the diagnosis of AHA diagnosis. The symptoms were noticeably alleviated following bortezomib, cyclophosphamide and dexamethasone therapy. This report describes a rare case of AHA associated with bullous pemphigoid and multiple myeloma. These pathologies induce an immunity modification that can predispose or be associated with the development of anti-FVIII inhibitors. This case illustrates two possible physiopathological hypotheses for the development of AHA, which will be discussed in this case report.
Extensive ecchymosis and retroperitoneal hemorrhage due to acquired hemophilia-A following influenza vaccination: A case report

Chi Sheuan Chin,Shinn-Jye Liang

DOI: https://doi.org/10.1097/md.0000000000038300

IF: 1.6

2024-05-26

Medicine

Abstract:Introduction: Acquired hemophilia-A (AHA) is a rare but potentially life-threatening impaired coagulation disorder characterized by the development of autoantibodies against clotting factor VIII. Only a few case reports have been experienced with influenza vaccine-triggered AHA. Here, we report a case of severe hemorrhagic disorder due to AHA following influenza vaccine, which was successfully treated. Patient concerns: The patient presented to the emergency department because of several severe, progressively worsening bruises after receiving the influenza vaccination. Consequently, the patient required intubation due to nasal-oral bleeding, which compromised the airway, and retroperitoneal hemorrhage with shock also developed. Diagnosis: AHA was confirmed through a coagulation factor assay, including coagulation activity and antibody testing, which is possibly triggered by influenza vaccination. Intervention: Low-dose cyclophosphamide and hydrocortisone were prescribed until activated partial thromboplastin time showed normal levels. Coagulation factor VIIa was administered, and aggressive blood transfusion was carried out concurrently to address the blood loss. Outcomes: The upper airway bleeding subsided and bleeding tendencies had been corrected to normal. The patient was smoothly weaned from the ventilator and recovered from critical illness. She was then discharged on the 19th day. Lessons: The activated partial thromboplastin time mixing test can be performed immediately to establish the initial differential diagnosis and treatment plan for severe coagulopathy. AHA may be triggered by vaccination, with the hypothesis of activation of autoantibodies and molecular mimicry; this mechanism should be further studied.

medicine, general & internal

Pathogenesis of peptic ulcer.

A Rare Case of Acquired Factor VIII Deficiency in an Elderly Male With a History of Rheumatoid Arthritis

Zik1, a Transcriptional Repressor That Interacts with the Heterogeneous Nuclear Ribonucleoprotein Particle K Protein*

Elimination of antibacterial activities of non-peptide luteinizing hormone-releasing hormone (LHRH) antagonists derived from erythromycin A.

Recognition of the unique bleeding pattern and laboratory findings in acquired haemophilia A facilitates prompt treatment of a life-threatening disorder

Acquired hemophilia A in a woman with systemic lupus erythematosus: A case report and review of literature

Acquired Hemophilia: A Rare Complication of Pediatric Idiopathic Multicentric Castleman Disease

Chemicals introduced in the processing of foods.

Acquired hemophilia A with venous thrombosis:report of a case and review of the literature

Postpartum Acquired Hemophilia A

[Systemic Lupus Erythematosus with Acquired Hemophilia A: a Case Report].

Retroperitoneoscopic renal pedicle lymphatic disconnection for chyluria.

Acquired hemophilia A as a disease of the elderly: A comprehensive review of epidemiology, pathogenesis, and novel therapy

Acquired bleeding disorders

S3627 Acquired Hemophilia A as a Cause of Obscure Gastrointestinal Bleeding

Acquired Hemophilia A Diagnosed Based on Gross Hematuria: A Case Report and Literature Review

Acute Abdominal Crisis in Type A Hemophilia: Unraveling Retroperitoneal Hematoma: A Case Report

Acquired hemophilia associated with bullous pemphigoid: a case report

Acquired Factor VIII Deficiency Presenting as Gross Hematuria in a Hispanic, Pregnant Patient with Previously Undiagnosed Connective Tissue Disease

[Acquired hemophilia A associated with bullous pemphigoid and multiple myeloma: a case report]

Extensive ecchymosis and retroperitoneal hemorrhage due to acquired hemophilia-A following influenza vaccination: A case report